Prne
September 7th, 2009
CAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is committed to doing everything possible to assist Gaucher patients and their physicians during the imiglucerase supply shortage. Shire is pleased to be able to provide velaglucerase alfa well over a year ahead of previously anticipated commercial launch world wide.
In the U.S., the velaglucerase alfa treatment protocol is currently open and enrolling patients. In the EU and other regions, Shire is engaging with national and regional authorities to seek pre-approval access using the fastest mechanisms available in each region. Shire will manage, on an ongoing basis, the overall global supply of velaglucerase alfa based on the evolving need as communicated to us by physicians.
Shire has accelerated its manufacturing timeline by almost 18 months in order to provide velaglucerase alfa for the long-term treatment of Gaucher patients during 2009 and beyond. Shire currently has supply of velaglucerase alfa for several hundred patients world-wide. The total number of patients Shire can treat is dependent on the patient weight, as well as the administered dose as recommended by their treating physician; Shire estimates this could translate into a range of 300 to 600 patients for uninterrupted treatment starting in September 2009. Shire also expects that several hundred more patients can be added throughout 2010; the range will again depend on patient weight, and doses.
Shire is working with a global group of experienced Gaucher physicians to ensure that physicians put in place guidelines that consider patients in the greatest need of treatment during the supply crisis. Individual treatment decisions will remain with the patient’s physician.
In addition, Shire is working with regulatory authorities towards the approval of velaglucerase alfa and has announced, earlier last week, that based on the positive results from all phase 3 trials, it has submitted the New Drug Application to the U.S. Food & Drug Administration and is expected to submit the EU application by year end.
In order to help physicians plan with their patients, Shire has today sent a letter to physicians in the U.S. This letter is to be posted on www.gaucherpatients.com.
Notes to editors
Shire plc
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
“SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
For further information please contact: Investor Relations Cléa Rosenfeld (Rest of the World) +44-1256-894-160 Eric Rojas (North America) +1-617-551-9715 Media Jessica Mann (Rest of the World) +44-1256-894-280 Jessica Cotrone (North America) +1-617-613-4640
Source: Shire Plc
For further information please contact: Investor Relations, Cléa Rosenfeld (Rest of the World), +44-1256-894-160; Eric Rojas (North America), +1-617-551-9715, Media, Jessica Mann (Rest of the World), +44-1256-894-280; Jessica Cotrone (North America), +1-617-613-4640
Filed under Biotechnology, Business, Health, Health Care / Hospitals, Pharmaceuticals, Surveys / Polls / Research | Tags: Cambridge, Massachusetts, Shire Plc, United States of America | Comment Below
Related Press Releases Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III TrialsAugust 31st, 2009 CAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported that it has completed its submission of a New Drug Application (NDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration (FDA). Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDAAugust 2nd, 2009 LEXINGTON, Massachusetts -
- Treatment Protocol Accepted and Rolling Submission of New Drug Application Initiated
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease. The Company also announced that the U.S. GONAL-f Approved in Japan for Ovulation Induction in Infertile WomenJuly 15th, 2009 GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the Japanese Ministry of Health, Labor and Welfare has granted approval to extend the indication of GONAL-f(R) (follitropin alfa for injection) to infertile women suffering from irregular or no ovulation (oligoovulation or anovulation) due to a dysfunction in the hypothalamic- pituitary system or polycystic ovarian syndrome. GONAL-f is a recombinant follicle-stimulating hormone currently approved in Japan for the treatment of male infertility. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher DiseaseJuly 15th, 2009 LEXINGTON, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type I Gaucher disease. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher DiseaseJuly 5th, 2009 LEXINGTON, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that, at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment for Gaucher Disease patients, it has filed a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Gaucher Disease. If approved by the FDA, the treatment protocol would allow physicians to treat Gaucher Disease patients with velaglucerase alfa ahead of commercial availability in the US. Merck Serono Launches "Global Fertility Academy" to Provide Education and Training for the Treatment of InfertilityJune 30th, 2009 GENEVA, Switzerland -
- Global Fertility Academy Delivers Valuable Educational Tools Aiming at Increasing Expertise and Maximizing the Success Rate of Treatment
- Web-based e-Learning Modules Complemented by Individualized Practical Training Sessions at Leading Fertility Centers Worldwide
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the launch of the Global Fertility Academy, the first global professional educational program in fertility run by worldwide leading experts in this area.(1) Specifically developed for physicians active in treating infertility, such as reproductive endocrinologists, obstetricians/gynecologists and embryologists, the Global Fertility Academy aims at improving their knowledge of clinical standards in fertility and maximizing the success rates of treatment by providing valuable educational tools and sharing best practices. The Global Fertility Academy is available to healthcare professionals outside of the United States and Great Britain. Merck Serono Committed to Investing in Innovation in the Fertility AreaMay 17th, 2009 GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, confirms its commitment to investing in the therapeutic area of fertility, after Merck KGaA informed earlier today the Oslo Stock Exchange of its withdrawal of the voluntary cash tender offer for MediCult A/S, a leader in Assisted Reproductive Technologies (ART), as the required share threshold was not reached in the set timeframe. "Merck Serono has a proud heritage of leadership in the field of fertility and will actively pursue opportunities that will contribute to bring further innovation to physicians and patients, and increase the success rate of fertility treatments," said Dr. ICS Update on Zambian OperationsApril 20th, 2009 ABBOTSFORD, Canada - ICS Copper Systems Ltd. (ICX:TSX.V) wishes to provide shareholders with the following update on recent activities:
Under the current extremely difficult market conditions which have impacted severely on the exploration and mining sector, ICS management has applied an overall strategy of reducing expenditures to a minimum, creating cash flow through the sale of some assets as well as continuing to proactively seek for new business opportunities. Newly Published Study Shows That Re-Treatment With Pegasys(R) (Peginterferon Alfa-2a) Provides Hepatitis C Patients With a Second Chance for a CureApril 19th, 2009 BASEL, Switzerland - New data published today in a major peer-reviewed journal, Annals of Internal Medicine, show that re-treatment with Pegasys(R) (peginterferon alfa-2a) plus Copegus(R) (ribavirin) provides previously-treated hepatitis C patients a second chance for a cure. The study results demonstrated that patients most likely to respond to re-treatment could be identified after only 12 weeks, allowing patients and their doctors to be confident early on about the likelihood of success.(1)
"While tremendous advances in hepatitis C treatment have cured many hepatitis C patients, a significant proportion of patients do not achieve success with their first treatment course. European Commission Approves ReFacto AF(TM) as a Variation to the Refacto(R) Marketing AuthorisationMarch 10th, 2009 MAIDENHEAD, England - Improvements in Purification Process Represent Important Advance in the
Treatment of Haemophilia A
Wyeth announced today it has received a positive decision from the
European Commission for a variation of the marketing authorisation for
ReFacto moroctocog alfa (Recombinant Coagulation Factor VIII), a treatment
for haemophilia A. The manufacturing process for ReFacto has been modified,
and the name has been changed to ReFacto AF moroctocog alfa (Recombinant
Coagulation Factor VIII).
Related News Arrogant Russian construction tycoon admits his company is nearly bustAugust 21st, 2009 Russian tycoon admits his companyMOSCOW — A Russian construction magnate who made headlines for saying that anyone who failed to become a billionaire in Russia is a loser has admitted that his once titanic company is going under. Mirax Group CEO Sergei Polonsky, who was worth $1.2 billion in 2008 according to Forbes magazine, posted a letter on his blog late Thursday saying that the company would stop all construction. Russian construction magnate admits his company has nearly gone bust; stops work on projectsAugust 21st, 2009 Russian tycoon acknowledges company going underMOSCOW — A Russian construction magnate who made headlines for saying that anyone who failed to become a billionaire in Russia is a loser has admitted that his once titanic company is going under. Mirax Group CEO Sergei Polonsky, who was worth $1.2 billion in 2008 according to Forbes magazine, posted a letter on his blog late Thursday saying that the company would stop all construction. Norway's Telenor fails to block sale of Vimpelcom stake through Russian courtsJuly 28th, 2009 Telenor fails to block sale of VimpelCom stakeMOSCOW — A Moscow court refused Tuesday to block the sale of Telenor's stake in No. 2 Russian mobile phone company VimpelCom, paving the way for the Norwegian company to lose its Russian asset, Telenor said in a statement. Russian bailiffs preparing to sell Telenor stake in Vimpelcom to recover $1.7 billion owedJune 8th, 2009 Russian bailiffs set to sell Telenor stakeMOSCOW — Russian bailiffs said Monday they are preparing to sell most of Norwegian telecom company Telenor's 29.9 percent stake in VimpelCom, Russia's No. 2 mobile phone operator, to recover $1.7 billion owed in damages. A look at some of the future products Chrysler and Fiat are planning for the US marketJune 10th, 2009 Products planned by the new Fiat-led ChryslerNew products from Chrysler in 2010:
— Redesigned, lighter and more fuel-efficient Jeep Grand Cherokee sport utility vehicle. — Reworked Chrysler 300C large sedan, which had been a top seller for the company until it was caught and passed by newer vehicles from other automakers. Fiat to takeover historic carmaker Bertone to design future cars for ChryslerAugust 6th, 2009 Fiat takes over historic carmaker BertoneMILAN — The Italian automaker Fiat on Thursday won a bid to take over the bankrupt Italian car company Bertone, which will help design cars for the U.S. automaker Chrysler, the Italian Economic Development Ministry said. Fiat posts $531M 1Q loss; Report: Fiat in talks to take majority stake in GM's Adam OpelApril 23rd, 2009 Fiat posts $531M 1Q loss; Report: Opel talksMILAN, Italy — Fiat Group SPA, which is in the final stretch of talks to take a possible minority stake in the U.S. automaker Chrysler, on Thursday reported its first quarterly loss since the turnaround engineered by CEO Sergio Marchionne, as sales of autos plummeted due to the global economic crisis. Fiat CEO affirms commitment to Chrysler deal, repeats won't put in cashApril 23rd, 2009 Fiat CEO affirms commitment to Chrysler dealMILAN — Fiat Group CEO Sergio Marchionne says the Italian automaker has an "unwavering commitment" to its proposed alliance with Chrysler but reiterates Fiat won't put in cash. Marchionne told an analyst conference call on Thursday that Fiat would not put in cash for a minority stake, but would only commit cash further down the road "at the relevant time as the need arises."
Fiat is offering technology in return for 20 percent of Chrysler ahead of an April 30 deadline set by the U.S. Fiat reports $410 million ($531 million) in 1Q losses with volumes down in all businessesApril 23rd, 2009 Fiat reports $410 million Q1 lossMILAN, Italy — Fiat Group SPA, which is in the final stretch of talks to take a possible minority stake in the U.S. automaker Chrysler, says it made a first-quarter loss of euro410 million ($530.83 million) as sales of autos plummeted due to the global economic crisis. Fiat reports $410 million ($531 million) loss in 1st qtr with volumes down in all businessesApril 23rd, 2009 Fiat reports $410 million first quarter lossMILAN, Italy — Fiat Group SPA, which is in the final stretch of talks to take a possible minority stake in the U.S. automaker Chrysler, says it made a first-quarter loss of euro410 million ($530.83 million) as sales of autos plummeted due to the global economic crisis.
|
|
